MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/mmy/myag008

Медицинская библиотека · Medical mycology · 2026

Opportunistic fungal infection risk and mortality in non-HIV, non-transplant US adults receiving systemic glucocorticoids: An observational cohort study.

Chastain Daniel B, Thompson George R, Tuo Ya, Henao-Martínez Andrés F

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

The dose-dependent risk of opportunistic fungal infections and associated mortality from systemic glucocorticoids remains poorly defined in non-HIV, non-transplant (NHNT) populations. This study evaluated the cumulative incidence of opportunistic fungal infections and the association between glucocorticoid dose, infection risk, and 1-year mortality in NHNT adults. In this observational cohort study (NCT05707156), adults without HIV or solid organ transplants who received systemic glucocorticoids for ≥14 days between 2022 and 2024 were identified using the TriNetX research network. Glucocorticoid doses, standardized to prednisone equivalents (PEQ), were categorized as ≤10 mg/day, 11-20 mg/day, and >20 mg/day based on clinically relevant thresholds. Cumulative duration beyond the initial ≥14 days was unavailable. Multivariable logistic regression identified predictors of opportunistic fungal infections. Cox proportional hazards and Kaplan-Meier analyses evaluated associations between glucocorticoid dose and 1-year all-cause mortality. Among 7839 patients, 6% developed opportunistic fungal infections, predominantly histoplasmosis (96%). Compared with ≤10 mg/day, neither 11-20 mg/day (OR 0.85, 95% CI 0.18-3.91) nor >20 mg/day (OR 0.89, 95% CI 0.24-3.33) was independently associated with infection risk. Crude 1-year mortality was higher in the >20 mg group (1.1%) versus ≤10 mg (0.5%) and 11-20 mg (0.4%) groups (P = .002), but glucocorticoid dose was not independently associated with mortality after adjustment. Increased mortality was associated with older age (HR 1.03/year), female sex (HR 1.96), and higher Charlson Comorbidity Index (HR 1.17 per point). Higher glucocorticoid doses did not independently predict opportunistic fungal infection risk or mortality, illustrating the limitations of dose-based risk stratification.

Для цитирования: Chastain Daniel B, Thompson George R, Tuo Ya, Henao-Martínez Andrés F. Opportunistic fungal infection risk and mortality in non-HIV, non-transplant US adults receiving systemic glucocorticoids: An observational cohort study.. Medical mycology. 2026. DOI: 10.1093/mmy/myag008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.